OpenAI has acquired the biotech startup Orchestra Bio to strengthen its position in life sciences research. This move brings Orchestra's team and technology under OpenAI's umbrella, enhancing its biotech business.
According to TechCrunch, OpenAI plans to integrate Orchestra's resources into the development of Rosalind, its AI model focused on life sciences, along with the Rosalind Workbench tool designed to support research in this field.
This acquisition highlights growing interest in AI-driven biotech innovation, an area that is increasingly relevant to Japanese markets where pharmaceutical and technology sectors are actively exploring AI applications.